Showing results (161-170 of 307) with videos related to
Sort By:
Pageof 31
Journal of Molecular Medicine (Berlin, Germany)|February 14, 1998
Candida sake: a relevant species in the context of HIV-associated oropharyngeal candidosis?L Hoegl, G Schönian, M Ollert, et al.Dermatologica|January 1, 1991
Do cutaneous coryneform bacteria produce short-chain fatty acids in vitro?A Lukacs, H C Korting, G Ruckdeschel, et al.Mycoses|June 21, 2002
[Mode of action of ciclopiroxolamine on Candida albicans]M Niewerth, M Schaller, H C Korting, et al.Journal of Clinical Microbiology|December 1, 1988
In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virusH C Korting, M Ollert, A Georgii, et al.Journal of the American Academy of Dermatology|December 1, 1989
Liposome preparations: a step forward in topical drug therapy for skin disease? A reviewM Schäfer-Korting, H C Korting, O Braun-FalcoMolecular Microbiology|August 28, 1998
Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavityM Schaller, W Schäfer, H C Korting, et al.Zeitschrift Fur Hautkrankheiten|January 18, 1988
[In vitro effectiveness of ofloxacin and ciprofloxacin in genital Chlamydia trachomatis isolates measured by minimal inhibitory concentration and minimal bactericidal concentration]A Hartinger, H C Korting, U Neubert, et al.International Journal of Cosmetic Science|May 21, 2008
Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgarisT Pavicic, U Wollenweber, M Farwick, et al.The Clinical Investigator|December 1, 1994
Liposomal tretinoin for uncomplicated acne vulgarisM Schäfer-Korting, H C Korting, E Ponce-PöschlDrug Safety|June 1, 1996
Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new conceptM Schäfer-Korting, M H Schmid, H C KortingPageof 31